Interpace Diagnostics' ThyGenX Test
PDI's molecular diagnostic subsidiary, Interpace Diagnostics, has launched a next-generation sequencing-based panel to assess cancer risk of thyroid nodules. The test, called ThyGenX, is an eight-gene panel to help physicians distinguish between benign and malignant genotypes in indeterminate thyroid nodules.